18016-80-3 Usage
Uses
Used in Pharmaceutical Industry:
S-(-)-LISURIDE is used as an anti-parkinson agent for its ability to alleviate the symptoms of Parkinson's disease by modulating the activity of dopamine and serotonin receptors in the brain. Its high affinity for these receptors allows for more effective treatment of the motor and non-motor symptoms associated with the disease.
Used in Research Applications:
In addition to its clinical use, S-(-)-LISURIDE is also utilized as a research tool in neuroscience and pharmacology. Its interaction with multiple receptor types makes it a valuable compound for studying the complex mechanisms underlying dopamine and serotonin signaling pathways, as well as their role in various neurological and psychiatric disorders.
Used in Drug Development:
The unique receptor binding profile of S-(-)-LISURIDE also makes it a promising candidate for the development of new drugs targeting the dopamine and serotonin systems. Researchers can use S-(-)-LISURIDE as a starting point for designing novel therapeutics that may have improved efficacy, reduced side effects, or new indications for use in treating a range of neurological and psychiatric conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 18016-80-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,0,1 and 6 respectively; the second part has 2 digits, 8 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 18016-80:
(7*1)+(6*8)+(5*0)+(4*1)+(3*6)+(2*8)+(1*0)=93
93 % 10 = 3
So 18016-80-3 is a valid CAS Registry Number.
InChI:InChI=1/C20H26N4O/c1-4-24(5-2)20(25)22-13-9-10-17-15(11-13)14-7-6-8-16-19(14)18(12-21-16)23(17)3/h6-8,11-13,17,21H,4-5,9-10H2,1-3H3,(H,22,25)
18016-80-3Relevant academic research and scientific papers
Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis
-
, (2008/06/13)
A composition for the treatment of endometritis in mammalian females which comprises as the physiologically active component a 1-(8alpha-ergolinyl)-3,3-diethylurea of the general formula I in which R1 represents an alkyl group containing from 1 to 3 carbon atoms, R2 represents a hydrogen atom or an alkyl group containing from 1 to 3 carbon atoms and either X stands for a hydrogen atom or both of them form jointly an additional bond between carbon atoms in positions 9 and 10, or a pharmaceutically acceptable acid addition salt thereof. The subject composition of the invention is suitable for treating acute puerperal inflammations and chronic endometritis in mammalian females, especially farm animal females, e.g. cows.
SOLVOLYSIS OF SOME 1-(8α-ERGOLINYL)-3,3-DIETHYLUREAS AND THEIR SALTS
Cerny, Antonin,Benes, Jan,Vachek, Jaroslav,Pesak, Milan,Stuchlik, Josef,et al.
, p. 1331 - 1339 (2007/10/02)
Nine salts of 1-(8α-ergolinyl)-3,3-diethylurea (II) were prepared and their solubility in water and the stability of the aqueous solutions at 60 and 100 deg C were studied.The main product of hydrolysis is 6-methyl-8α-aminoergoline IV.The urethan VII is formed in the ethanolic solution.Both decomposition products are also formed under long-term storage at +5 deg C.The course of hydrolysis of N-propyl homologue III is similar.The decomposition of 9,10-didehydro derivative I is much slower under the conditions used.
